XF-73

chemical compound

Uses your system voice; voice and rate in settings.

Q8041945Snapshot

≈ 1 min read

Names in other languages

  • اردوایکس ایف-73
  • EnglishXF-73
  • shXF-73
  • СрпскиXF-73

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

XF-73 (Exeporfinium chloride) is an experimental drug candidate. It is an anti-microbial that works via weakening bacteria cell walls. It is a potential treatment for methicillin-resistant Staphylococcus aureus (MRSA) and possibly Clostridioides difficile.

It is being developed by Destiny Pharma Ltd. Structurally, it is a dicationic porphyrin. It has completed a phase I clinical trial for nasal decolonisation of MRSA—being tested against 5 bacterial strains. It seems unlikely to cause MRSA to develop resistance to it.

In 2014, a phase 1 clinical trial for nasal administration was run. , another phase 1 clinical trial (for nasal administration) completed recruiting in 2016 but no results have been posted.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1362522586 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

11 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.